Skip to main content
Caplight Logo









Hope Medicine

Hope Medicine

Private
ShanghaiHealthcare & Life Scienceshttps://hopemedinc.com/

Last Round

Series B

Extension

Feb 8, 2024

Total Funding Raised

$84.1M

Company Overview

Hope Medicine is a biopharmaceutical company that develops and commercializes medicines for endocrine, cardiovascular, and metabolic diseases, with a special focus on women's health.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share

AI Layer

Non-AI

Keywords

monoclonal antibodyendometriosis treatmentmAbsfirst-in-class therapiesnon-hormonal treatmentandrogenetic alopecia treatmentwomen's healthPRLR antagonistclinical stage biotechhair loss treatmentbiopharmabiologic drugsfemtechdrug in-licensingcardiovascular therapies

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Hope Medicine Comparables

Compare Hope Medicine with similar companies based on industry and business-model similarity.

Hope Medicine comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Gesynta Pharma AB
78%
EndoCyclic Therapeutics
74%
Organon & Co.
74%

Hope Medicine Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series B ExtensionFeb 8, 2024
Series BMay 6, 2021
Series AApr 8, 2019

Hope Medicine Investors

Notable investors and investment history

Hope Medicine investors
InvestorRounds
HighLight CapitalSeries B
VMS Asset ManagementSeries B Extension
Sinovation VenturesSeries B Extension, Series B
Wuxi Capital Group Co.,LtdSeries B Extension
Trustbridge PartnersSeries B Extension, Series B, Series A
Ennovation VenturesSeries B Extension
Qiming Venture PartnersSeries B Extension, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 8, 2024

    $28.1M round led by VMS Asset Management and Wuxi Capital Group.

  • May 6, 2021

    $56M round led by Grand Flight Investment and Qiming Venture Partners.

Hope Medicine Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Hope Medicine Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Hope Medicine's valuation, stock price, and market status.

Firmographic Details

HeadquartersShanghai
Year Founded2018
Last FundingFeb 8, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?